PMID- 34184475
OWN - NLM
STAT- MEDLINE
DCOM- 20210630
LR  - 20220531
IS  - 1997-7298 (Print)
IS  - 1997-7298 (Linking)
VI  - 121
IP  - 5
DP  - 2021
TI  - [Therapy of moderate cognitive impairment in the early recovery period of 
      ischemic stroke].
PG  - 33-39
LID - 10.17116/jnevro202112105133 [doi]
AB  - OBJECTIVE: To assess the efficacy and safety of prospecta in the treatment of 
      moderate cognitive impairment in the early recovery period of ischemic stroke. 
      MATERIAL AND METHODS: The study included 275 patients (mean age 64.0+/-8.1 years) 
      with a history of single ischemic stroke from 3 to 6 months, with moderate 
      cognitive impairment, and moderate activity in everyday life, who were randomized 
      in two groups. During the screening phase, the severity of cognitive impairment 
      was assessed with the Mini-Mental State Examination and Montreal Cognitive 
      Assessment scales; the level of activity in everyday life was evaluated with the 
      Barthel Scale; and quality of life was assessed with the Stroke Specific Quality 
      of Life Scale. Patients took 2 tablets of prospecta or placebo 2 times a day for 
      24 weeks. The follow-up period was 4 weeks. The primary endpoint of the study was 
      the proportion of patients with improvement in cognitive function (+1 or more on 
      the MoCA test) after 24 weeks of treatment. The occurrence and type of adverse 
      events (AEs), their severity, relationship to the drug, outcome, changes in vital 
      signs, and the proportion of patients with clinically significant abnormality in 
      laboratory tests were analyzed to assess the safety. RESULTS: A clinically 
      significant improvement in cognitive function was obtained in 91.9% of patients 
      in the prospecta group vs 82.,1% in the placebo group, (p=0.02). There were 57 
      AEs in 37 (27.4%) Prospecta group patients and 53 AEs in 39 (27.9%) Placebo group 
      participants (p=1.00). No AEs were certainly associated with taking the 
      medication. No clinically significant changes in vital signs or abnormal 
      laboratory results were detected during the study. CONCLUSION: Prospecta is an 
      effective and safe treatment option for patients with moderate cognitive 
      impairment in the early recovery period of ischemic stroke.
FAU - Belova, A N
AU  - Belova AN
AUID- ORCID: 0000-0001-9719-6772
AD  - Privolzhsky Research Medical University, Nizhniy Novgorod, Russia.
FAU - Bogdanov, E I
AU  - Bogdanov EI
AUID- ORCID: 0000-0001-9332-8053
AD  - Kazan State Medical University, Kazan, Russia.
FAU - Voznyuk, I A
AU  - Voznyuk IA
AUID- ORCID: 0000-0002-0340-4110
AD  - Dzhanelidze St. Petersburg Research Institute of Emergency Medicine, St. 
      Petersburg, Russia.
FAU - Zhadnov, V A
AU  - Zhadnov VA
AUID- ORCID: 0000-0002-5973-1196
AD  - Pavlov Ryazan State Medical University, Ryazan, Russia.
FAU - Kamchatnov, P R
AU  - Kamchatnov PR
AUID- ORCID: 0000-0001-6747-3476
AD  - Pirogov Russian National Research Medical University, Moscow, Russia.
FAU - Kurushina, O V
AU  - Kurushina OV
AUID- ORCID: 0000-0003-4364-0123
AD  - Volgograd State Medical University, Volgograd, Russia.
FAU - Maslova, N N
AU  - Maslova NN
AUID- ORCID: 0000-0003-0183-5643
AD  - Smolensk State Medical University, Smolensk, Russia.
LA  - rus
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Terapiya umerennykh kognitivnykh rasstroistv v rannem vosstanovitel'nom periode 
      ishemicheskogo insul'ta.
PL  - Russia (Federation)
TA  - Zh Nevrol Psikhiatr Im S S Korsakova
JT  - Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
JID - 9712194
SB  - IM
MH  - Aged
MH  - *Brain Ischemia/complications/drug therapy
MH  - *Cognitive Dysfunction/drug therapy/etiology
MH  - Humans
MH  - *Ischemic Stroke
MH  - Middle Aged
MH  - Quality of Life
MH  - *Stroke/complications/drug therapy
OTO - NOTNLM
OT  - early recovery
OT  - ischemic stroke
OT  - moderate cognitive impairment
OT  - prospecta
EDAT- 2021/06/30 06:00
MHDA- 2021/07/01 06:00
CRDT- 2021/06/29 07:04
PHST- 2021/06/29 07:04 [entrez]
PHST- 2021/06/30 06:00 [pubmed]
PHST- 2021/07/01 06:00 [medline]
AID - 10.17116/jnevro202112105133 [doi]
PST - ppublish
SO  - Zh Nevrol Psikhiatr Im S S Korsakova. 2021;121(5):33-39. doi: 
      10.17116/jnevro202112105133.